Medpage Today on MSN12d
Novel Drug Improved Symptoms in Eosinophilic Esophagitis
The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...
The Globe and Mail13d
Eosinophilic Esophagitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone ...
Health Rounds: No need to stop GLP-1 drugs before surgery for most patients
In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...
6abc News6d
Recognizing EOE, a digestive disorder probably triggered by an allergic reaction
Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...
Dupixent® (Dupilumab) Approved In The European Union As The First And Only Medicine For Young Children With Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...
Celldex’s Promising Pipeline and Undervaluation Justify Buy Rating
Celldex (CLDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archila ...
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
PDUFA date for potential approval of Zanidatamab is set for Nov 29, developed in collaboration with Jazz Pharmaceuticals and BeiGene. Find out why ZYME stock is a Buy.
Celldex: Strong Buy Rating Amid Promising Pipeline and Attractive Valuation
In a report released yesterday, David Lebowitz from Citi maintained a Buy rating on Celldex (CLDX – Research Report), with a price target ...